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2Abstract
Background:  Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders 
(NMOSD) are autoimmune demyelinating diseases distinguished clinically by selective 
involvement in NMOSD of optic nerves and spinal cord. Early clinical manifestations are 
similar, complicating clinical management. Aquaporin-4 autoantibody measurement aids 
diagnosis of NMOSD but is frequently negative, creating unmet need for alternative 
biomarkers.  
Objective: We investigated whether plasma complement proteins are altered in MS and 
NMOSD and whether these provide biomarkers that reliably distinguish the diseases.
Methods: Plasma from 53 NMOSD, 49 MS and 69 control donors was tested in multiplex 
assays measuring complement activation products and proteins. Logistic regression was used 
to test whether combinations of complement analyte measurements distinguish NMOSD from 
controls and MS.
Results: All activation products were significantly elevated in NMOSD compared to either 
control or MS. Four complement proteins (C1inh, C1s, C5, FH) were significantly higher in 
NMOSD compared to MS or controls. A model comprising C1 inhibitor and TCC 
distinguished NMOSD from MS (area under curve (AUC) 0.98), while C1 inhibitor and C5 
distinguished NMOSD from controls (AUC 0.94).  
Conclusions: NMOSD is distinguished from MS by plasma complement activation. 
Selective complement analyte measurement enables differential diagnosis and supports the 
case for anti-complement therapy in NMOSD.  
3Introduction
Neuromyelitis optica spectrum disorder (NMOSD) describes a spectrum of rare autoimmune 
demyelinating disorders predominantly affecting the optic nerves, spinal cord and 
periependymal regions of the brain;1 consensus diagnostic criteria were recently published.2
Patients usually present with relapsing episodes of optic neuritis and/or longitudinally 
extensive transverse myelitis, or more rarely, brainstem syndromes, including intractable 
hiccups. The presenting features of NMOSD can be similar, and in some cases
indistinguishable, from those of the much commoner CNS demyelinating disease multiple 
sclerosis (MS) so that misdiagnosis, particularly in early disease, is common. However, 
NMOSD and MS are distinct diseases, each requiring early diagnosis and specific therapeutic 
strategies for optimal management.3-5
In 2004, Lennon et al  demonstrated autoantibodies against the water channel aquaporin-4 
(AQP4) in the serum of patients with NMOSD.6,7 AQP4-Abs were subsequently found to be 
highly specific for NMOSD and likely pathogenic.8,9 However, a proportion of patients
fulfilling clinical criteria for NMOSD, 20-40% in Caucasians and likely higher in some other 
ethnic groups, are AQP4-Ab negative.10 Some of these AQP4-Ab negative patients have 
recently been shown to have autoantibodies against myelin oligodendrocyte glycoprotein 
(MOG) and demonstrate specific clinical features, which also suggest differences in 
pathogenesis.11-13 It is likely that many of the residual autoantibody-negative patients harbour 
as yet unidentified pathological antibodies.
There is substantial evidence that complement activation drives pathology in NMOSD, 
particularly in AQP4-Ab positive cases. The AQP-4 autoantibody response is predominantly 
IgG1, a potent complement activator,14 and complement activation products, including the 
4terminal complement complex (TCC), are deposited in NMOSD lesions.15,16 In vivo studies 
have shown that disease can be transferred to mice by infusion of patient-derived AQP4-Abs; 
these cause complement-mediated astrocyte destruction followed by myelin loss, gliosis and 
neuronal death.17-19 Despite the evidence implicating complement, there is a paucity of 
studies exploring either central or peripheral complement activation in patients.  This is an 
important knowledge gap since an understanding of complement activation in NMOSD 
would not only inform understanding of pathogenesis but also provide potential biomarkers 
for diagnosis and stratification for therapy.  Here we have developed multiplexed assay sets 
to interrogate complement activation and levels of key complement proteins in NMOSD 
plasma.  We demonstrate that plasma levels of complement activation products and some 
components reliably differentiate NMOSD from either MS or normal controls. These findings 
demonstrate that peripheral complement activation, evidenced by altered plasma markers, is 
markedly greater in NMOSD than in MS; further, they show that a subset of plasma 
complement biomarkers clearly differentiate the two diseases. Complement activation was 
greater in autoantibody-positive NMOSD patients, but several complement analytes were 
significantly different between autoantibody-negative NMOSD and MS. A model derived 
from the best differentiating analytes was highly predictive with overall predictive power 
(from area under the curve [AUC] in receiver-operating characteristic [ROC] analysis) of 
0.94 for NMOSD versus control and 0.98 for NMOSD versus MS.  Complement biomarkers 
are relatively easy to measure and we suggest that an optimal set of the markers implicated 
here will provide a useful additional tool for the diagnosis of NMOSD, including in the 
diagnostically challenging AQP4-Ab-negative patients; critically, these measures also enable 
differentiation from MS. 
Methods
5Samples: EDTA plasma samples from 40 MS patients, 54 NMOSD patients and 69 healthy 
controls were obtained from the Welsh Neuroscience Research Tissue Bank, Institute of 
Neurosciences and Mental Health, Cardiff University. Informed consent was obtained from 
all patients and ethical approval was gained from South East Wales Ethics Committee (ref 
no.05/WSE03/111). MS cases were classified as clinically definite relapsing-remitting MS on 
long-term follow-up according to accepted contemporary diagnostic criteria.20 All MS cases 
had undergone diagnostic and follow-up magnetic resonance imaging (MRI) as part of 
routine clinical care.  Data on age at onset, age at sampling, years of follow-up, relapse rate, 
expanded disability status scale (EDSS) at time of sampling, proximity of sampling to most 
recent relapse, and whether on disease-modifying therapy (DMT) and/or prednisolone at time 
of sampling were captured (Table 1). Five of the MS patients (3 female, two male; mean age 
at onset 36; follow-up 13 years) had predominantly opticospinal disease.
All patients with NMOSD were reviewed and the diagnosis confirmed by a neurologist with 
experience in the diagnosis and management of neuroinflammatory disorders including 
NMOSD (NR, SL). All NMOSD cases had undergone diagnostic and follow-up magnetic 
resonance imaging (MRI) as part of routine clinical care. AQP4-Ab and MOG-Ab status was 
assessed at the Clinical Neuroimmunology Service, John Radcliffe Hospital Trust, Oxford 
UK.21,22 Thirty-nine of the NMOSD samples were AQP4-Ab positive, 7 were MOG-Ab 
positive and 8 were autoantibody-negative (Table 1). 
Assay development and multiplexing. Ten complement analytes were selected for this 
study, 5 components or regulators (C1s, C3, C5, C1inh, FH), and 5 activation products (iC3b, 
C4d, Bb, C5a and TCC).  Analyte choice was informed by reference to previous studies of 
complement biomarkers in MS, and availability of reagents; the activation marker set was 
chosen to interrogate classical (C4d, iC3b), alternative (Bb, iC3b) and terminal (C5a, TCC) 
activation pathways. For each analyte, an antibody pair was selected from commercial or in-
6house sources (Table 2) and tested in ELISA for capacity to detect the analyte in plasma 
using purified proteins as standards. Selected antibody pairs were then tested in single-plex 
electrochemiluminescence (ECL) assays using high-bind plates from “ELISA Conversion 
Pack I” (MesoScale Discovery Platform [MSD], Rockville, Maryland, USA). Detection 
antibodies were conjugated to SULFO-TAG with ratio 1:12 according to the manufacturer’s 
instructions. Single-plex assays were validated for reproducibility (intra- and inter-assay 
Coefficient of Variation [CV] <10%), sensitivity and dynamic range.  For each analyte the 
range of plasma dilutions that enabled accurate quantitation was assessed; the optimal plasma 
dilution for measurement of all analytes in the set was then selected. Two five-plex plates (all 
analytes measured in a single well), one comprising an activation marker set and the other a 
component/regulator set, as noted above, were printed by MSD using the supplied capture 
antibodies, and re-validated for reproducibility, sensitivity and dynamic range and to confirm 
that all included analytes could be measured at a single plasma dilution. Each five-plex plate 
was also tested with mixtures of the relevant analyte standards to ensure that there was no 
“cross-talk” between assays. 
The assay protocol was as follows: Printed plates were blocked with 150µl/well 3% BSA in 
PBS at 4°C overnight. Plasma samples were diluted (1: 1000 for the activation marker set; 1: 
4000 for the component/regulator set) in assay buffer (PBS containing 1% BSA and 10 mM 
EDTA) and 25µl of diluted sample was added to duplicate wells and incubated while shaking 
at ambient for 60 min. After washing in PBS containing 0.01% Tween20, a mixture of the 
relevant SULFO-TAG-labelled detection antibodies diluted in assay buffer (1:100) was added 
and incubated as before. After washing, 150µl of 2x reading buffer was added to each well 
and ECL signal was immediately registered in a Sector S600 plate reader (MSD).  A standard 
curve comprising six 5-fold dilutions of pre-mixed standard proteins was run in duplicate on 
the same plate and ECL values in plasma samples automatically converted to analyte 
7concentration by reference to the standard curve. A standardized plasma sample was used as 
inter-plate control.
Statistical methods. All statistical analysis was conducted in GraphPad Prism version 5 (La 
Jolla, CA, USA) and R version 3.0.2.  Logistic regression was used to analyse the association 
of analyte concentration with diagnosis.  The analytes which were most strongly associated 
with diagnosis (based on p value) were then combined into one model.  Any analytes which 
were not significant after inclusion in the model were discarded.  Receiver-operating 
characteristic (ROC) curves were drawn and area under the curve (AUC) for the final model 
was calculated, and compared to that for individual analytes.  Clustered mixed-effects linear 
modelling (using the lme4 and lmerTest R packages) was used to explore the associations 
between analyte concentration and disease status.  AUC was used to define the predictive 
power of individual analytes or the analyte set that comprised the model.
Results
Complement protein assays are sensitive and specific in multiplex formats.   Each of the 
complement analyte assays translated from ELISA, through single-plex to multiplex without 
loss of performance. There was no detectable inter-assay interference between the different 
analytes in the multiplexes and intra- and inter-assay CVs were <10% for all analytes.
Complement activation products are elevated in NMOSD plasma compared to MS or 
healthy controls.  Five complement activation products, relevant to classical (C4d, iC3b),
alternative (Bb, iC3b) and terminal (C5a, TCC) pathways were measured in the available 
plasma samples (Figure 1). Three of these (Bb, iC3b, TCC) were significantly lower in MS 
compared with controls. Each of the measured activation products was significantly higher in 
NMOSD plasma compared to either MS or controls; iC3b and TCC were the strongest 
discriminators (each with p<0.005). Comparison of AQP4-Ab positive, MOG-Ab positive 
8and antibody-negative NMOSD samples showed a clear trend in values of activation markers 
AQP4-Ab+>MOG-Ab+>Antibody-negative for Bb, C4d and C5a and MOG-Ab +>AQP4-Ab 
+>Antibody-negative for iC3b and TCC (Table 3).  Levels of each of the activation products 
were significantly higher in AQP4-Ab positive samples compared to MS but only TCC and 
iC3b were significantly different compared to MS in the MOG-Ab positive and antibody-
negative NMOSD groups, likely because of the small number of samples in these groups. 
Five of the 40 MS patients in the cohort had opticospinal-dominant disease; there was no 
obvious difference in complement analyte levels in this subgroup compared to the whole MS 
group, although the numbers were too small for formal statistical evaluation. Clinical 
parameters were tested across all groups for correlation with complement analyte levels; no 
significant correlation with any complement analyte was seen for age at onset, follow-up 
years, relapse rate, proximity to relapse, or treatment at time of sampling (negative data not 
shown). EDSS was weakly correlated with each of the activation products in the NMOSD 
group; however, EDSS was high in all patients in this group, likely masking the correlation. 
MRI data was not available at time of sampling so was not tested as a covariate. 
Complement proteins and regulators are elevated in NMOSD plasma compared to MS 
or healthy controls.  Five complement proteins/regulators were measured in the available 
plasma samples (Figure 2). One of these, C1s, was significantly lower in MS compared to 
controls. Four (C1inh, C1s, C5 and FH) were significantly elevated in NMOSD plasma 
compared to MS and normal controls.  C3 levels were lower in NMOSD plasma than in MS 
or normal controls. Comparison of AQP4-Ab positive, MOG-Ab positive and antibody-
negative NMOSD samples showed very similar levels of increase in C1inh, C1s, C5 and FH 
in each of the groups (Table 3); C3 levels were significantly lower only in the AQP4-Ab 
positive NMOSD group compared to MS or controls.
A model comprising two complement analytes optimally differentiates NMOSD from 
9controls. Logistic regression analysis demonstrated that each of the complement analytes 
measured significantly distinguished NMOSD from controls. The three most significant of 
these based on p value, C1inh, C5 and FH, were combined in a model (Table 4); FH was 
removed from the model after testing because it did not significantly add to the model. AUC 
from a model to differentiate NMOSD from controls combining C1inh and C5 was 0.938, 
considered highly predictive (Figure 3A).     
Two complement analytes optimally differentiate NMOSD from MS. Logistic regression 
analysis demonstrated that each of the complement analytes measured significantly 
distinguished NMOSD from MS. The three most significant of these based on p value, C1inh, 
FH and TCC, were combined in a model (Table 4); after testing, FH was removed from the 
model because it did not significantly add to the model. AUC from a model to differentiate 
NMOSD from MS combining C1inh and TCC was 0.977, considered highly predictive 
(Figure 3B).     
Discussion
A plasma marker or marker set that is highly predictive of NMOSD and, critically, 
distinguishes NMOSD from MS, is a current unmet need.  Numerous analytes, notably 
cytokines and other inflammatory markers, have been tested but none has yet proven reliable 
in replication studies (recently reviewed by Melamed et al).23 AQP4 autoantibody tests, 
where available, are highly specific for NMOSD, but even the best available tests have a 
sensitivity no better than 80%, and even lower in some ethnic groups, because of the 
frequency of AQP4-Ab negative patients.22,23 Some of these are positive for MOG 
autoantibodies (7/54 in our series);21,24 however, a significant proportion (8/54 in our series) 
remain autoantibody negative, although it is likely that these harbour as-yet unidentified 
pathological autoantibodies. Critically, AQP4 autoantibody titres correlate poorly with 
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disease severity, response to therapy or outcome.25 We reasoned that complement represented 
a likely source of biomarkers given the evidence, summarised in the introduction, that 
complement drives pathology in NMOSD, and the recent demonstration that anti-
complement therapies impact the disease.26,27 We explored whether selected complement 
analytes, or a composite signature derived from complement biomarkers, might provide a test 
that could supplement autoantibody measures in order to improve diagnostic certainty, 
particularly in AQP4-Ab negative NMOSD, and enable reliable differentiation from MS 
thereby reducing the possibility of iatrogenic therapeutic morbidity.4,5,28
A limited number of studies have examined complement proteins and activation products in 
NMOSD with conflicting results. In 2011, Tuzun et al measured Bb, C4d and TCC in plasma 
from 28 NMOSD and 29 MS cases;29 all three of these activation markers were elevated in 
NMOSD compared to MS or healthy controls, the latter two significantly, leading the authors 
to suggest that NMOSD differed from MS “by predominance of complement system 
involvement”. Kuroda et al measured C3a, C4a and C5a in serum and CSF from NMOSD in 
relapse (15), MS in relapse (15) and other neurological disease (OND) controls (12);30 none 
of the serum markers were significantly different between the groups but CSF C5a was 
significantly elevated in NMOSD compared to MS and OND and correlated with lesion 
number detected by imaging. Wang et al also reported increased CSF levels of C5a and TCC 
in NMOSD.31 Veszeli et al described a “systematic analysis” of complement in 25 AQP4-Ab 
positive NMOSD patients in remission compared to healthy controls;32 classical and lectin 
pathway activities were higher and complement proteins C3, FI, FB and properdin were 
reduced in NMOSD plasma. Surprisingly, activation products C3a, C3bBbP and TCC were 
reduced in NMOSD plasma compared to controls. C1inh and C5 were measured in this study 
and were not different in NMOSD compared to controls. Nytrova et al measured C3a, C4a, 
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TCC and anti-C1q in anti-Aqp4-positive NMOSD (19), MS (35) and control (40) plasmas;33
C3a and TCC were significantly increased in NMOSD compared to controls but not MS 
while C4a was significantly reduced in NMOSD compared to both MS and controls. C3a 
correlated with disease severity in NMOSD and differentiated patients with recent (past 6 
months) relapse from those without recent relapse. Together, these publications reveal a lack 
of consensus regarding the relevance of complement and complement activation in NMOSD; 
although the majority describe elevated levels of complement activation products centrally in 
CSF and/or peripherally in plasma, some describe the opposite, provoking concern about the 
reliability of assays. 
Using well-validated and quality-controlled multiplex assays, we found clear evidence of 
peripheral complement activation in NMOSD; each of the activation markers, indicative of 
classical (C4d, iC3b), alternative (Bb, iC3b) and terminal (C5a, TCC) pathway activation, 
was significantly elevated in NMOSD plasma compared to either MS or control plasma. 
Notably, none of the activation pathway markers was significantly elevated in MS plasma 
compared to controls. We previously reported that plasma levels of Bb and TCC were not 
elevated in MS compared to controls, while C4a was elevated but only in acute relapse.34,35
These data demonstrate that complement activation represents a fundamental difference 
between the two diseases; peripheral evidence of complement activation (impacting all 
pathways) is specific to NMOSD.  We concur with the conclusion of Tuzun et al that 
NMOSD differs from MS “by predominance of complement system involvement”.29 In our 
study, levels of activation products were highest in autoantibody-positive disease, either 
AQP4-Ab or MOG-Ab; each of the activation products was increased in AQP4-Ab positive 
NMOSD compared to MS but only TCC and iC3b were significantly increased in the MOG-
Ab positive and antibody-negative NMOSD groups compared to MS. The demonstration of 
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ongoing complement activation in the antibody-negative group supports the suggestion that 
these individuals harbour as yet unidentified pathogenic autoantibodies. These complement 
activation markers measured individually provide strong differentiation between the diseases. 
The complement proteins C1inh, C1s, C5 and FH were significantly elevated in NMOSD 
plasma regardless of autoantibody status compared to MS and normal controls, while C3 
levels were lower only in AQP4-Ab positive NMOSD. The mechanism(s) underpinning these 
changes are uncertain but likely represent the balance between increased synthesis as a part of 
the acute phase response and increased consumption due to complement activation.
In order to identify the most predictive set of complement analytes from our data, we 
generated models that selected combinations of analytes that provided complementary 
information to increase discriminatory power. The first model compared NMOSD cases with 
MS cases and included the three most significant analytes C1inh, FH and TCC; FH did not 
improve the model and was discarded.  ROC curves constructed using just C1inh and TCC 
gave an AUC of 0.977 for distinguishing NMOSD from MS, considered “highly 
predictive”.36 The second model compared NMOSD cases with controls and included the 
three most significant analytes FH, C1inh and C5; FH did not improve the model and was 
discarded. ROC curves constructed using just C1inh and C5 gave an AUC of 0.938 for 
distinguishing NMOSD from controls, considered “highly predictive”. These findings 
demonstrate that measurement of just three complement analytes in patient samples, a simple 
task with modern multiplexing, provides a near-perfect predictive test for diagnosis of 
NMOSD and for distinguishing NMOSD from MS. The findings suggest that measurement 
of complement analytes together with autoantibodies may in the future become accepted 
clinical practice in the diagnosis and monitoring of NMOSD; however, further work is 
needed to replicate these findings in independent cohorts and to establish whether
13
complement analytes are associated with disease activity, suggested here for the activation 
products.
We have here shown that combinations of complement biomarkers can aid diagnosis of 
demyelinating diseases and enable differentiation between MS and NMOSD. Importantly, 
complement activation and protein biomarkers were elevated not only in autoantibody-
positive NMOSD but also in autoantibody-negative cases, albeit to a lesser degree, providing 
potential biomarkers for this difficult patient subset and revealing clues to the underlying 
pathology. These findings suggest that complement activation occurs even in the absence of 
detectable autoantibodies, a finding that may impact understanding of pathogenesis in 
autoantibody-negative NMOSD. These data may also influence the future use of complement 
inhibitory drugs in NMOSD where studies to date have been restricted to AQP4-Ab positive 
disease.26
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NMOSD MS Healthy 
ControlFeature With AQP4-Ab Without AQP4-Ab
With MOG-Ab Seronegative
Number 39 6 8 40 69
Female, n (%) 37 (94.9) 5 (83.3) 3 (27.3) 31 (63.3) 44 (63.8)
Caucasian, n (%) 36 (92.3) 6 (100) 6 (100) 35 (87.5) 65* (94.2)
Age at sampling, 
mean (SD)
53.8 (17.2) 43.5 (18.4) 53.0 (11.3) 41.2 (9.2) 35.6 (8.2)
Age at onset, mean 
(SD)
41.7 (17.9) 31.4 (14.6) 41.4 (17.4) 31.6 (10.2) NA NA
Follow up, mean 
(SD)
10.5 (8.5) 10.5 (8.9) 12.0 (15.0) 13.2 (2.8) NA NA
Attacks per patient, 
mean (SD)
6.0 (4.8) 6.1 (5.0) 5.1 (2.9) 8.2 (6.3) NA NA
Annualised relapse 
rate, mean (SD)
0.79 (0.5) 0.81 (0.5) 1.05 (0.8) 0.62 (0.5) NA NA
Table 1: Demographic and clinical profile of patients and controls enrolled in the study. 
Abbreviations: AQP4-Ab, seropositive for IgG against aquaporin-4; MOG-Ab, seropositive 
for IgG against myelin-oligodendrocyte glycoprotein; NA, Not Applicable; MS, multiple 
sclerosis; NMOSD, Neuromyelitis Optica Spectrum Disorder; SD, standard deviation. * The 
ethnicity of 4 of the healthy controls was not recorded.
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Assay Capture 
antibody
Detection 
antibody
Standard Working 
range 
(ng/ml)
Sample 
dilution
Activation marker set
Bb MM anti-neo Bb 
(Quidel)
MM anti-FB 
(JC1, in-house)
Bb Fragment 
(Comptech)
1.6-5000 1 in 1000
C4d MM anti-neo 
C4d (Quidel)
MM anti-C4d 
(Quidel)
Recombinant C4d
(Gifted)*
1.6-5000 1 in 1000
iC3b MM anti-neo 
iC3b (Hycult)
MM anti-C3
(C3-30, in-
house)
iC3b
(Comptech)
1.6-5000 1 in 1000
C5a MM anti-neo 
C5a (Hycult)
MM anti-C5 
(Hycult)
C5a desArg 
(Comptech)
1.6-5000 1 in 1000
TCC MM anti-neo C9 
(aE11, Hycult)
MM anti-C8
(E2, in-house)
TCC
(in-house 
purified)
1.6-5000 1 in 1000
Component set
C1-
INH
MM anti-C1inh
(KK, in-house)
MM anti-C1inh 
(3C3, in-house)
C1inhibitor
(Cinryze drug)
0.32-1000 1 in 4000
C1s MM anti-C1s
(M81, Hycult)
MM anti-C1s
(F33, in-house)
C1s proenzyme 
(Comptech)
0.32-1000 1 in 4000
C3 MM anti-C3
(HC3-1, in-
house)
RP C3
(in house)
C3
(Comptech)
0.32-1000 1 in 4000
C5 RP anti-human 
C5 (in-house)
MM anti-C5 
(Hycult)
C5
(Comptech)
0.32-1000 1 in 4000
FH MM anti-FH 
(OX-24, in-
house)
RP anti-FH
(in-house)
FH 
(in-house 
purified)
0.32-1000 1 in 4000
Table 2: Design of assays used in the multiplex sets.
The table lists the antibody pairs used in the multiplex sets, the sources of the antibodies and 
the standards, dilutions and assay working range. * A kind gift from Dr D Isenman, Toronto, 
Canada. Quidel, https://www.quidel.com/; Hycult, http://www.hycultbiotech.com/; Comptech, 
http://www.complementtech.com/. Abbreviations: MM, mouse monoclonal antibody; RP, 
rabbit affinity purified polyclonal antibody.
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Analyte Anti-Aqp-4 +ve
(n=39) Mean ± SD
Anti-MOG +ve
(n=6) Mean ± SD
Autoantibody -ve 
(n=8) Mean ± SD
Activation marker set
Bb 3.37 ± 2.19 2.94 ± 1.93 2.22 ± 1.11
C4d 3.46 ± 1.80 2.94 ± 1.70 2.38 ± 0.71
C5a 0.03 ± 0.02 0.02 ± 0.01 0.01 ± 0.00
TCC 0.72 ± 0.33 0.86 ± 0.36 0.66 ± 0.37
iC3b 77.60 ± 25.54 81.12 ± 33.29 75.46 ± 38.64
Component set
C1-INH 169.90 ± 26.25 182.20 ± 33.17 169.00 ± 38.40
C1s 136.20 ± 37.51 127.70 ± 31.48 98.59 ± 31.67
C3 706.30 ± 176.40 780.10 ± 219.90 864.60 ± 246.60
C5 165.00 ± 31.08 163.70 ± 32.99 117.50 ± 39.66
FH 322.20 ± 75.38 339.10 ± 45.83 268.40 ± 87.87
Table 3. Complement activation products and components in NMOSD subgroups. All 
values are mean concentration in µg/ml plus or minus one standard deviation (SD). 
β (95% CI) P
MS NMOSD versus controls
C1inh 0.03 (0.01-0.06) 0.00352
C5 0.04472 (0.02-0.07) 9.75x10-5 
NMOSD versus
C1inh 0.06 (0.02 - 0.09) 0.001278
TCC 9.60 (5.51 - 13.68) 0.000622
Table 4. Regression analysis NMO versus controls and NMOSD versus MS. Clustered 
mixed-effects linear modelling (using the lme4 and lmerTest R packages) was used to explore 
the associations between analyte concentration and disease status.  The analytes which were 
most strongly associated with diagnosis (based on p value) were then combined into the final 
model. Any analytes which were not significant after inclusion in the model were discarded.
21
Figure 1. Plasma levels of activation products in NMOSD and MS patients compared with 
normal controls.  Plasma concentrations of classical (C4d, iC3b), alternative (Bb, iC3b) and 
terminal (C5a, TCC) pathway activation products were measured in NMOSD (53 samples), 
MS (40 samples) and controls (69 samples). Results are in µg/ml for all analytes. Significant 
differences between groups are shown; *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001. 
The inserted Table summarises means and SDs for each analyte.
Figure 2. Plasma levels of complement components and regulators in NMOSD and MS 
patients compared with normal controls. Plasma concentrations of selected complement 
proteins and regulators were measured in NMOSD (53 samples), MS (40 samples) and controls 
(69 samples). Results are in µg/ml for all analytes. Significant differences between groups are 
shown; *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001. The inserted Table summarises 
means and SDs for each analyte.
Figure 3. Receiver-operating characteristic (ROC) curves representing models which 
differentiates NMOSD from controls (A) and NMOSD from MS (B). ROC curves were 
drawn for the final models distinguishing NMOSD from controls (A; C1inh and C5) and 
NMOSD from MS (B; C1inh and TCC). The area under the curve (AUC) for the final model 
was calculated, and compared to that for the individual analytes.  AUC was used to define the 
predictive power of the analyte or analyte set that comprised the model; the predictive power 
of the model for distinguishing NMOSD from MS was 0.977, and for distinguishing NMOSD 
from controls was 0.938.
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